Skip to main content

Advertisement

SpringerLink
Log in

Venous thromboembolism in hematopoietic stem cell transplant recipients

  • Review
  • Published:
Bone Marrow Transplantation Submit manuscript

Abstract

Venous thromboembolism (VTE) is an increasingly recognized problem in the post-hematopoietic stem cell transplantation (HSCT) setting, with a lack of high-quality evidence-based data to recommend best practices. Few patients with hematologic malignancies and even fewer post-HSCT patients were included in randomized trials of VTE prophylaxis and treatment. Prior VTE, GVHD, infections and indwelling venous catheters are risk factors for thrombosis. The increasing use of post-transplant maintenance therapy with lenalidomide in patients with multiple myeloma adds to this risk after autologous HSCT. These patients are also at high risk of bleeding complications because of prolonged thrombocytopenia and managing the competing risks of bleeding and thrombosis can be challenging. This review aims to provide a practical, clinician-focused approach to the prevention and treatment of VTE in the post-HSCT setting.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Chew HK, Wun T, Harvey D, Zhou H, White RH . Incidence of venous thromboembolism and its effect on survival among patients with common cancers. Arch Intern Med 2006; 166: 458–464.

    Article  PubMed  Google Scholar 

  2. Khorana AA . Malignancy, thrombosis and trousseau: the case for an eponym. J Thromb Haemost 2003; 1: 2463–2465.

    Article  CAS  PubMed  Google Scholar 

  3. Sørensen HT, Mellemkjaer L, Olsen JH, Baron JA . Prognosis of cancers associated with venous thromboembolism. N Engl J Med 2000; 343: 1846–1850.

    Article  PubMed  Google Scholar 

  4. Gross CP, Galusha DH, Krumholz HM . The impact of venous thromboembolism on risk of death or hemorrhage in older cancer patients. J Gen Intern Med 2007; 22: 321–326.

    Article  PubMed  PubMed Central  Google Scholar 

  5. Yu YB, Gau JP, Liu CY, Yang MH, Chiang SC, Hsu HC et al. A nation-wide analysis of venous thromboembolism in 497,180 cancer patients with the development and validation of a risk-stratification scoring system. Thromb Haemost 2012; 108: 225–235.

    Article  CAS  PubMed  Google Scholar 

  6. Seifter EJ, Young RC, Longo DL . Deep venous thrombosis during therapy for Hodgkin’s disease. Cancer Treat Rep 1985; 69: 1011–1013.

    CAS  PubMed  Google Scholar 

  7. Ottinger H, Belka C, Kozole G, Engelhard M, Meusers P, Paar D et al. Deep venous thrombosis and pulmonary artery embolism in high-grade non Hodgkin’s lymphoma: incidence, causes and prognostic relevance. Eur J Haematol 1995; 54: 186–194.

    Article  CAS  PubMed  Google Scholar 

  8. Ku GH, White RH, Chew HK, Dj Harvey, Zhou H, Wun T . Venous thromboembolism in patients with acute leukemia: incidence, risk factors, and effect on survival. Blood 2009; 113: 3911–3917.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Vu K, Luong NV, Hubbard J, Zalpour A, Faderl S, Thomas DA et al. A retrospective study of venous thromboembolism in acute leukemia patients treated at the University of Texas MD Anderson Cancer Center. Cancer Med 2015; 4: 27–35.

    Article  PubMed  Google Scholar 

  10. Falanga A, Marchetti M . Venous thromboembolism in the hematologic malignancies. J Clin Oncol 2009; 27: 4848–4857.

    Article  CAS  PubMed  Google Scholar 

  11. Mailloux A, Grenet K, Bruneel A, Beneteau-Burnat B, Vaubourdolle M, Baudin B . Anticancer drugs induce necrosis of human endothelial cells involving both oncosis and apoptosis. Eur J Cell Biol 2001; 80: 442–449.

    Article  CAS  PubMed  Google Scholar 

  12. Kansu E . Thrombosis in stem cell transplantation. Hematology 2012; 17: S159–S162.

    Article  CAS  PubMed  Google Scholar 

  13. Khorana AA, Francis CW, Culakova E, Kuderer NM, Lyman GH . Frequency, risk factors, and trends for venous thromboembolism among hospitalized cancer patients. Cancer 2007; 110: 2339–2346.

    Article  PubMed  Google Scholar 

  14. Garcia-Maldonado M, Kaufman CE, Comp PC . Decrease in endothelial cell-dependent protein C activation induced by thrombomodulin by treatment with cyclosporine. Transplantation 1991; 51: 701–705.

    Article  CAS  PubMed  Google Scholar 

  15. Talamo GP, Ibrahim S, Claxton D, Tricot GJ, Fink LM, Zangari M . Hypercoagulable states in patients with multiple myeloma can affect the thalidomide-associated venous thromboembolism. Blood Coagul Fibrinolysis 2009; 20: 337–339.

    Article  CAS  PubMed  Google Scholar 

  16. Kazory A, Ducloux D, Coaquette A, Manzoni P, Chalopin JM . Cytomegalovirus-associated venous thromboembolism in renal transplant recipients: a report of 7 cases. Transplantation 2004; 77: 597–599.

    Article  PubMed  Google Scholar 

  17. Gerber DE, Segal JB, Levy MY, Kane J, Jones RJ, Streiff MB . The incidence and risk factors for venous thromboembolism (VTE) and bleeding among 1514 patients undergoing hematopoietic stem cell transplantation: implications for VTE prevention. Blood 2008; 112: 504–510.

    Article  CAS  PubMed  Google Scholar 

  18. Pihusch R, Salat C, Schmidt E, Gohring P, Pihusch M, Hiller E et al. Hemostatic complications in bone marrow transplantation: a retrospective analysis of 447 patients. Transplantation 2002; 74: 1303–1309.

    Article  PubMed  Google Scholar 

  19. Labrador J, Lopez-Anglada L, Perez-Lopez E, Lozano FS, Lopez-Corral L, Sanchez-Guijo FM et al. Analysis of incidence, risk factors and clinical outcome of thromboembolic and bleeding events in 431 allogeneic hematopoietic stem cell transplantation recipients. Haematologica 2013; 98: 437–443.

    Article  PubMed  PubMed Central  Google Scholar 

  20. Tsakiris DA, Marbet GA, Tichelli A, Gratwohl A, Speck B . Activation of endothelium-dependent hemostatic factors following bone marrow transplantation. Schweiz Med Wochenschr 1995; 125: 416–419.

    CAS  PubMed  Google Scholar 

  21. Kaufman PA, Jones RB, Greenberg CS, Peters WP . Autologous bone marrow transplantation and factor XII, factor VII and protein C deficiencies: report of a new association and its possible relationship to endothelial cell injury. Cancer 1990; 66: 515–521.

    Article  CAS  PubMed  Google Scholar 

  22. Verheij M, Dewit LG, Boomgaard MN, Brinkman HJ, van Mourik JA . Ionizing radiation enhances platelet adhesion to the extracellular matrix of endothelial cells by an increase in the release of von Willebrand factor. Radiat Res 1994; 137: 202–207.

    Article  CAS  PubMed  Google Scholar 

  23. Vannucchi AM, Rafanelli D, Longo G, Bosi A, Guidi S, Saccardi R et al. Early haemostatic alterations following bone marrow transplantation: a prospective study. Haematologica 1994; 79: 519–525.

    CAS  PubMed  Google Scholar 

  24. Catani L, Gugliotta L, Vianelli N, Nocentini F, Baravelli S, Bandini G et al. Endothelium and bone marrow transplantation. Bone Marrow Transplant 1996; 17: 277–280.

    CAS  PubMed  Google Scholar 

  25. Haire WD . Antithrombin III in hematopoietic stem cell transplantation. Semin Thromb Hemost 1997; 23: 591–601.

    Article  CAS  PubMed  Google Scholar 

  26. Brandao LR, Kletzel M, Boulad F, Kurtzberg J, Maloney K, Fligman I et al. A prospective longitudinal multicenter study of coagulation in pediatric patients undergoing allogeneic stem cell transplantation. Pediatr Blood Cancer 2008; 50: 1240–1246.

    Article  PubMed  Google Scholar 

  27. DiCarlo J, Agarwal-Hashmi R, Shah A, Kim P, Craveiro L, Killen R et al. Cytokine and chemokine patterns across 100 days after hematopoietic stem cell transplantation in children. Biol Blood Marrow Transplant 2014; 20: 361–369.

    Article  CAS  PubMed  Google Scholar 

  28. Dumler JS, Beschorner WE, Farmer ER, Di Gennaro KA, Sara lR, Santos GW . Endothelial-cell injury in cutaneous acute graft-versus-host disease. Am J Pathol 1989; 135: 1097–1103.

    CAS  PubMed  PubMed Central  Google Scholar 

  29. Holler E, Kolb HJ, Moller A, Kempeni J, Liesenfeld S, Pechumer H et al. Increased serum levels of tumor necrosis factor alpha precede major complications of bone marrow transplantation. Blood 1990; 75: 1011–1016.

    CAS  PubMed  Google Scholar 

  30. Gonsalves A, Carrier M, Wells PS, McDiarmid SA, Huebsch LB, Allan DS . Incidence of symptomatic venous thromboembolism following hematopoietic stem cell transplantation. J Thromb Haemost 2008; 6: 1468–1473.

    Article  CAS  PubMed  Google Scholar 

  31. O'Hara VJ, Miller T, Mehta R, Swartzendruber E, Kiel PJ . Incidence of venous thromboembolism in the setting of hematopoietic cell transplantation. Am J Ther 2014; 21: 15–19.

    Article  PubMed  Google Scholar 

  32. Cortelezzi A, Moia M, Falanga A, Pogliani EM, Agnelli G, Bonizzoni E et al. Incidence of thrombotic complications in patients with haematological malignancies with central venous catheters: a prospective multicentre study. Br J Haematol 2005; 129: 811–817.

    Article  PubMed  Google Scholar 

  33. Weber LL, Dunbar NM, Dumont LJ, Szczepiorkowski ZM . Successful use of citrate anticoagulant with heparin bolus for excessive clotting during extracorporeal photopheresis. Transfusion 2012; 52: 2494–2495.

    Article  PubMed  Google Scholar 

  34. Apisarnthanarax N, Donato M, Körbling M, Couriel D, Gajewski J, Giralt S et al. Extracorporeal photopheresis therapy in the management of steroid-refractory or steroid-dependent cutaneous chronic graft-versus-host disease after allogeneic stem cell transplantation: feasibility and results. Bone Marrow Transplant 2003; 31: 459–465.

    Article  CAS  PubMed  Google Scholar 

  35. Alikhan R, Cohen AT, Combe S, Samama MM, Desjardins L, Eldor A et al. Risk factors for venous thromboembolism in hospitalized patients with acute medical illness: analysis of the MEDENOX Study. Arch Intern Med 2004; 164: 963–968.

    Article  PubMed  Google Scholar 

  36. Samama MM . An epidemiologic study of risk factors for deep vein thrombosis in medical outpatients: the Sirius study. Arch Intern Med 2000; 160: 3415–3420.

    Article  CAS  PubMed  Google Scholar 

  37. Anderson FA Jr, Spencer FA . Risk factors for venous thromboembolism. Circulation 2003; 107: I9–I16.

    Article  PubMed  Google Scholar 

  38. Paul TM, Liu SV, Chong EA, Luger SM, Porter DL, Schuster SJ et al. Outpatient autologous stem cell transplantation for patients with myeloma. Clin Lymphoma Myeloma Leuk 2015; 15: 536–540.

    Article  PubMed  Google Scholar 

  39. Abdelkefi A, Ben Romdhane N, Kriaa A, Chelli M, Torjman L, Ladeb S et al. Prevalence of inherited prothrombotic abnormalities and central venous catheter-related thrombosis in haematopoietic stem cell transplants recipients. Bone Marrow Transplant 2005; 36: 885–889.

    Article  CAS  PubMed  Google Scholar 

  40. Van Rooden CJ, Rosendaal FR, Meinders AE, Van Oostayen JA, Van Der Meer FJ, Huisman MV . The contribution of factor V Leiden and prothrombin G20210A mutation to the risk of central venous catheter-related thrombosis. Haematologica 2004; 89: 201–206.

    CAS  PubMed  Google Scholar 

  41. Geerts W . Central venous catheter-related thrombosis. Hematology Am Soc Hematol Educ Program 2014; 2014: 306–311.

    Article  PubMed  Google Scholar 

  42. Chopra V, Anand S, Hickner A, Buist M, Rogers MA, Saint S et al. Risk of venous thromboembolism associated with peripherally inserted central catheters: a systematic review and meta-analysis. Lancet 2013; 382: 311–325.

    Article  PubMed  Google Scholar 

  43. Debourdeau P, Farge D, Beckers M, Baglin C, Bauersachs RM, Brenner B et al. International clinical practice guidelines for the treatment and prophylaxis of thrombosis associated with central venous catheters in patients with cancer. J Thromb Haemost 2013; 11: 71–80.

    Article  CAS  PubMed  Google Scholar 

  44. Luciani A, Clement O, Halimi P, Goudot D, Porteir F, Bassot V et al. Catheter-related upper extremity deep venous thrombosis in cancer patients: a prospective study based on Doppler US. Radiology 2001; 220: 655–660.

    Article  CAS  PubMed  Google Scholar 

  45. Verso M, Agnelli G, Bertoglio S, Di Somma FC, Paoletti F, Ageno W et al. Enoxaparin for the prevention of venous thromboembolism associated with central vein catheter: a double-blind, placebo-controlled, randomized study in cancer patients. J Clin Oncol 2005; 23: 4057–4062.

    Article  CAS  PubMed  Google Scholar 

  46. Grant JD, Stevens SM, Woller SC, Lee EW, Kee ST, Liu DM et al. Diagnosis and management of upper extremity deep-vein thrombosis in adults. Thromb Haemost 2012; 108: 1097–1108.

    Article  PubMed  Google Scholar 

  47. Lyman GH, Bohlke K, Khorana AA, Kuderer NM, Ay Lee, Arcelus JI et al. Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology Clinical Practice Guideline Update 2014. J Clin Oncol 2015; 33: 654–656.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  48. Kearon C, Akl EA, Comerota AJ, Prandoni P, Bounameaux H, Goldhaber SZ et al. Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141: e419S–e4194S.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  49. Kovacs MJ, Kahn SR, Rodger M, Anderson DR, Andreou R, Mangel JE et al. A pilot study of central venous catheter survival in cancer patients using low-molecular-weight heparin (dalteparin) and warfarin without catheter removal for the treatment of upper extremity deep vein thrombosis (the Catheter Study). J Thromb Haemost 2007; 5: 1650–1653.

    Article  CAS  PubMed  Google Scholar 

  50. Agnelli G, Gussoni G, Bianchini C, Verso M, Mandalà M, Cavanna L et al. Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study. Lancet Oncol 2009; 10: 943–949.

    Article  CAS  PubMed  Google Scholar 

  51. Agnelli G, George DJ, Kakkar AK, Fisher W, Lassen MR, Mismetti P et al. Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer. N Engl J Med 2012; 366: 601–609.

    Article  CAS  PubMed  Google Scholar 

  52. Streiff MB, Bockenstedt PL, Cataland SR, Chesney C, Eby C, Fanikos J et al. Venous thromboembolic disease. J Natl Compr Canc Netw 2013; 11: 1402–1429.

    Article  CAS  PubMed  Google Scholar 

  53. Connors JM . Prophylaxis against venous thromboembolism in ambulatory patients with cancer. N Engl J Med 2014; 370: 2515–2519.

    Article  PubMed  Google Scholar 

  54. Barlogie B, Tricot G, Anaissie E, Shaughnessy J, Rasmussen E, van Rhee F et al. Thalidomide and hematopoietic-cell transplantation for multiple myeloma. N Engl J Med 2006; 354: 1021–1030.

    Article  CAS  PubMed  Google Scholar 

  55. McCarthy PL, Owzar K, Hofmeister CC, Hurd DD, Hassoun H, Richardson PG et al. Lenalidomide after stem-cell transplantation for multiple myeloma. N Engl J Med 2012; 366: 1770–1781.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  56. Richardson PG, Siegel DS, Vij R, Hofmeister CC, Baz R, Jagannath S et al. Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study. Blood 2014; 123: 1826–1832.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  57. Leleu X, Attal M, Arnulf B, Moreau P, Traulle C, Marit G et al. Pomalidomide plus low-dose dexamethasone is active and well tolerated in bortezomib and lenalidomide-refractory multiple myeloma: Intergroupe Francophone du Myélome 2009-02. Blood 2013; 121: 1968–1975.

    Article  CAS  PubMed  Google Scholar 

  58. San Miguel J, Weisel K, Moreau P, Lacy M, Song K, Delforge M et al. Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial. Lancet Oncol 2013; 14: 1055–1066.

    Article  Google Scholar 

  59. Palumbo A, Cavo M, Bringhen S, Zamagni E, Romano A, Patriarca F et al. Aspirin, warfarin, or enoxaparin thromboprophylaxis in patients with multiple myeloma treated with thalidomide: A phase III, open-label, randomized trial. J Clin Oncol 2011; 29: 986–993.

    Article  CAS  PubMed  Google Scholar 

  60. Larocca A, Cavallo F, Bringhen S, Di Raimondo F, Falanga A, Evangelista A et al. Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide. Blood 2012; 119: 933–939.

    Article  CAS  PubMed  Google Scholar 

  61. Palumbo A, Rajkumar SV, Dimopoulos MA, Richardson PG, San Miguel J, Barlogie B et al. Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia 2008; 22: 414–423.

    Article  CAS  PubMed  Google Scholar 

  62. Samama MM, Cohen AT, Darmon JY, Desjardins L, Eldor A, Janbon C et al. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. N Engl J Med 1999; 341: 793–800.

    Article  CAS  PubMed  Google Scholar 

  63. Leizorovicz A, Cohen AT, Turpie AG, Olsson CG, Vaitkus PT, Goldhaber SZ . PREVENT Medical Thromboprophylaxis Study Group Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients. Circulation 2004; 110: 874–879.

    Article  CAS  PubMed  Google Scholar 

  64. Kanaan AO, Silva MA, Donovan JL, Roy T, Al-Homsi AS . Meta-analysis of venous thromboembolism prophylaxis in medically ill patients. Clin Ther 2007; 29: 2395–2405.

    Article  CAS  PubMed  Google Scholar 

  65. Young AM, Billingham LJ, Begum G, Kerr DJ, Hughes AI, Rea DW et al. Warfarin thromboprophylaxis in cancer patients with central venous catheters (WARP): an open-label randomised trial. Lancet 2009; 373: 567–574.

    Article  PubMed  Google Scholar 

  66. Carrier M, Tay J, Fergusson D, Wells PS . Thromboprophylaxis for catheter-related thrombosis in patients with cancer: a systemic review of the randomized controlled trials. J Thromb Haemost 2007; 5: 2552–2554.

    Article  CAS  PubMed  Google Scholar 

  67. Akl EA, Karmath G, Yosuico V, Yosuico VE, Barba M, Sperati F et al. Anticoagulation for thrombosis prophylaxis in cancer patients with central venous catheters. Cochrane Database Syst Rev 2007: (3): CD006468.

  68. Chaukiyal P, Nautiyal A, Radhakrishnan S, Singh S, Navaneethan SD . Thromboprophylaxis in cancer patients with central venous catheters. A systematic review and meta-analysis. Thromb Haemost 2008; 99: 38–43.

    Article  CAS  PubMed  Google Scholar 

  69. van der Hulle T, den Exter PL, Kooiman J, van der Hoeven JJ, Huisman MV, Klok FA . Meta-analysis of the efficacy and safety of new oral anticoagulants in patients with cancer-associated acute venous thromboembolism. J Thromb Haemost 2014; 12: 1116–1120.

    Article  CAS  PubMed  Google Scholar 

  70. Sarosiek S, Crowther M, Sloan JM . Indications, complications, and management of inferior vena cava filters: the experience in 952 patients at an academic hospital with a level I trauma center. JAMA Intern Med 2013; 173: 513–517.

    Article  PubMed  Google Scholar 

  71. National Clinical Guideline Center. Venous thromboembolic diseases: the management of venous thromboembolic diseases and the role of thrombophilia testing. Available from http://www.ncbi.nlm.nih.gov/books/NBK132796/. (accessed 8 April 2015).

  72. Hicks LK, Bering H, Carson KR, Kleinerman J, Kukreti V, Ma A et al. The ASH Choosing Wisely campaign: five hematologic tests and treatments to question. Blood 2013; 122: 3879–3883.

    Article  CAS  PubMed  Google Scholar 

  73. Browne AM, Cronin CG, English C, NiMhuircheartaigh J, Murphy JM, Bruzzi JF . Unsuspected pulmonary emboli in oncology patients undergoing routine computed tomography imaging. J Thorac Oncol 2010; 5: 798–803.

    Article  PubMed  Google Scholar 

  74. Desai SR . Unsuspected pulmonary embolism on CT scanning: yet another headache for clinicians? Thorax 2007; 62: 470–472.

    Article  PubMed  PubMed Central  Google Scholar 

  75. Khorana AA, O’Connell C, Agnelli A, Liebman HA, Lee AY . Subcommittee on hemostasis and malignancy of the SSC of the ISTH. Incidental venous thromboembolism in oncology patients. J Thromb Haemost 2012; 10: 2602–2604.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  76. den Exter PL, Hooijer J, Dekkers OM, Huisman MV . Risk of recurrent venous thromboembolism and mortality in patients with cancer incidentally diagnosed with pulmonary embolism: a comparison with symptomatic patients. J Clin Oncol 2011; 29: 2405–2409.

    Article  PubMed  Google Scholar 

  77. O'Connell C, Razavi P, Ghalichi M, Boyle S, Vasan S, Mark L et al. Unsuspected pulmonary emboli adversely impact survival in patients with cancer undergoing routine staging multi-row detector computed tomography scanning. J Thromb Haemost 2011; 9: 305–311.

    Article  CAS  PubMed  Google Scholar 

  78. Gussoni G, Frasson S, La Regina M, Di Micco P, Monreal M . RIETE Investigators. Three-month mortality rate and clinical predictors in patients with venous thromboembolism and cancer. Findings from the RIETE registry. Thromb Res 2013; 131: 24–30.

    Article  CAS  PubMed  Google Scholar 

  79. Chaturvedi S, Sidana S, Elson P, Khorana AA, McCrae KR . Symptomatic and incidental venous thromboembolic disease are both associated with mortality in patients with prostate cancer. PLoS ONE 2014; 9: e94048.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Hematology/Oncology, Department of Medicine, Hematology and Stem Cell Transplantation Section, Vanderbilt University Medical Center and Veterans Affairs Medical Center, Nashville, TN, USA

    S Chaturvedi & B N Savani

  2. Department of Hematologic Oncology and Blood Disorders, Benign Hematology Program, Cleveland Clinic, Cleveland, OH, USA

    A Neff

  3. Hematology Division, Department of Medicine, Chaim Sheba Medical Center, Tel Hahomer, Israel

    A Nagler

  4. University of Michigan, Ann Arbor, MI, USA

    U Savani

  5. Department of Haematology, Saint Antoine Hospital, Paris, France

    M Mohty

Authors
  1. S Chaturvedi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A Neff
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. A Nagler
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. U Savani
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. M Mohty
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. B N Savani
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to B N Savani.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Chaturvedi, S., Neff, A., Nagler, A. et al. Venous thromboembolism in hematopoietic stem cell transplant recipients. Bone Marrow Transplant 51, 473–478 (2016). https://doi.org/10.1038/bmt.2015.308

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/bmt.2015.308

  • Springer Nature Limited

This article is cited by

Search

Navigation